Nautilus Biotechnology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Nautilus Biotechnology, a development-stage life sciences company, reported a net loss of $59.0 million for 2025 as it continues to invest heavily in its Nautilus Voyager™ proteomics platform, targeting a phased commercial launch in late 2026.
NASDAQ
Nautilus Biotechnology's 2024 10-K filing highlights ongoing development of its proteomics platform and its commercialization strategy.
NASDAQ
Nautilus Biotechnology's 2023 annual report highlights its ongoing development of a proteomics platform, strategic partnerships, and a three-phase commercialization plan, while acknowledging significant net losses and the need for future capital.